Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery

Denong Wang*

Tumor Glycomics Laboratory, SRI International Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA, USA

Although the term “glyco code” has only recently come into use [1-4], recognition of the carbohydrate signatures of microbes was documented nearly a century ago. In 1917, Dochez and Avery [5] found that when *Pneumococci* were grown in fluid media, there was a substance in the culture fluid that precipitated specifically with antiserum to the same *Pneumococcus*. Heidelberger and Avery [6] showed that the substance recognized by the antibodies was a carbohydrate molecule and not a protein, as previously thought. It was later found that almost every microorganism expresses such glyco codes that are recognized by the host immune systems and are effective in stimulating specific antibody responses [7,8]. Such immunogenic carbohydrate moieties often serve as key targets for development of vaccines against infectious diseases [9-13]. Tumor glycomics research in recent years has uncovered a large panel of tumor-associated carbohydrate antigens [14,15] and evidence of immune recognition of tumor-derived aberrant carbohydrates [16-20].

Carbohydrates are capable of generating structural diversity in multiple ways and are prominently displayed on the surfaces of cell membranes or on the exposed regions of macromolecules. Unlike proteins, which are connected solely by a peptide bond, carbohydrates utilize many possible glycosidic linkages so as to extensively diversify their structures. Two amino acid residues, such as two alanines, can produce only one possible dipeptide; however, two molecules of glucose have the potential to generate 11 different disaccharides. A trimer of any of the nine common sugar residues of the human body theoretically can give rise to 119,736 different structural isomers; this is in striking contrast to the maximal construction of 8,000 tripeptides using 20 different amino acid residues. Theoretically, sugar chain structures can have unlimited variation.

Importantly, there are multiple carbohydrate-recognition systems in living species that “read” the biological information of complex carbohydrates. Two examples are the numerous anti-glycan antibodies produced by many animal species that play key roles in protecting a host from microbial infections [13,21,22] and the families of lectin-like glycan-binding proteins (GBPs) that are evolved for carbohydrate-mediated cell-cell communication [23-25]. Thus, carbohydrates are uniquely suitable for storing biological signals in the forms that are identifiable by other biological systems.

In the immunological and glycobiological literature, “glyco-epitope” is often used to specify the carbohydrate moiety that is recognized by an antibody or by a GBP. The antibody-binding glyco-epitopes are also classified as B cell epitopes or antigenic determinants. Conceptually, “glyco-epitope” refers to the entire repertoire of glyco-epitopes, including the B cell epitopes and those that are recognized by GBPs. Differing from “glycome,” which covers all the existing carbohydrate molecules in living organisms, glyco-epitome refers to a unique subset of carbohydrates that serve as the sugar signatures for molecular recognition and bio-signal transmission. “Glyco-epitomics” is, thus, an evolving area of glycomics research focusing on identifying, characterizing, and understanding the carbohydrate moieties that serve for multiple levels of bio-communication.

The structural aspects of glyco-epitomics focus on the elucidation of the glycan structures that display glyco-epitopes. This research area has been substantially enhanced by the development of advanced profiling and structural characterization strategies. Notably, these include high-resolution chromatography methods coupled with exoglycosidase digestions [26,27], modern mass spectrometry [28-30] and nuclear magnetic resonance spectroscopy analyses [31-33] of carbohydrates, and the state-of-art methods of glycan structural modeling [34,35].

However, availability of carbohydrate structural information alone is not sufficient in defining a glyco-epitope unless its specific binding by an antibody or a GBP is also demonstrated immunochromatically and/or crystallographically. For example, chemical determination of a tetrasaccharide that decorates the spore of *Bacillus anthracis* appears to be an important discovery in microbial glycomics [36]. Based on the past knowledge of immunogenic carbohydrate moieties, this structural glycomics progress may suggest that this unique sugar moiety may have potential in an immunological application [37,38]. However, whether such a carbohydrate moiety preserves a B cell epitope or a potent antigenic determinant must be determined immunologically, including at least demonstration of its antibody binding specificity and capacity in eliciting immune responses *in vivo* [10]. It was the integrated structural and immunological investigation with the support of carbohydrate microarray technologies [10,13] that has revealed anthrose-tetrasaccharides as key immunological targets of *B. anthracis*. Its applications may include identification of the presence of *B. anthracis* spores, surveillance and diagnosis of anthrax infection, and development of novel vaccines targeting the *B. anthracis* spore.

Modern carbohydrate microarrays emerged in 2002 [39-42] and introduced new glycomics tools to decipher the biological information content in the glycome. These technologies are especially useful in exploring the repertoire of glyco-epitopes. Given the structural characteristics of the carbohydrates displayed on chips, carbohydrate microarrays are classified into monosaccharide chips, oligosaccharide chips, and microarrays of carbohydrate-containing macromolecules. The latter includes polysaccharides and various glycoconjugates. These different sugar chips or arrays were developed to accommodate multipurpose applications in carbohydrate research. For example, the mono- and disaccharide microarrays are suitable for screening and characterizing carbohydrate-binding proteins or carbohydrate-

*Corresponding author: Denong Wang, Tumor Glycomics Laboratory, SRI International Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA- 94025, USA, Tel: (650) 859-2788; Fax: (650) 859-3153; E-mail: denong.wang@sri.com

Received February 20, 2014; Accepted February 22, 2014; Published February 25, 2014

Citation: Wang D (2014) Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery. J Proteomics Bioinform 7: e24. doi:10.4172/0974-276X.1000e24

Copyright: © 2014 Wang D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
glycan antibodies recognize larger and more complex carbohy-
protein interaction [43,44]. However, some lectins and many anti-
catalyzing enzymes and for identifying inhibitors of carbohydrate-
chips are not sufficient for investigations involving such molecular
chips. The oligosaccharide [10,45,46], polysaccharide [47,48], and
interaction come to fill this gap by displaying carbohydrates of complex structures or longer sugar chains on the
One of the important research areas in glyco-epitomics is the
understanding of the nature and characteristics of the immunogenic
sugar moieties that render them key targets for immunological and
clinical applications. Figure 1 illustrates an example that common
sugar residue glucose can form either non-immunogenic or highly
immunogenic polysaccharide molecules. The α(1,4)-linked glycosyl
polymer illustrated is the digestible, non-immunogenic glycogen. A
microbe-produced α(1,6)-dextran molecule is, however, immunogenic
in human and many animal species. This is owing to the fact that α(1,6)
dextran, but not α(1,4)glycogen, is resistant to the host enzymatic
digestion and persists in vivo to stimulate B cell responses. Thus,
whether a carbohydrate molecule is immunogenic is determined by
a complex process of antigen processing, host recognition, and the
regulated immune response to a target molecule.

A carbohydrate antigen, such as α(1,6)dextran (Figure 1, upper
panel), may display different types of epitopes, such as the terminal
and internal chain glyco-epitopes [8,34], on its solvent-accessible
surface. This can be attributed to the hydrophilic property of
carbohydrates, which makes them strikingly different from proteins.
In aqueous solution, proteins tend to fold to bring their hydrophobic
side chains together, forming an oily core with polar side chains
exposed. Surface moieties of a protein antigen may serve as antigenic
determinants interacting with B-cell Ig-receptors; interior residues are
generally not accessible to such interactions. Carbohydrates are built
up by monosaccharides, whereby the enriched hydroxy groups readily
interact with water molecules by hydrogen bonding. Their glycosidic
linkages are more flexible than the peptide bonds in proteins, and
protein-like folding patterns are not seen in polysaccharides. Thus,
not only are the terminals of the carbohydrate chains accessible for
molecular recognition but residues in the internal chain are also
exposed in solvent and are frequently reactive. Many carbohydrate-
based vaccines focus on the terminal non-reducing end epitopes,
leaving a large class of internal chain epitopes unexplored.

Identifying the immunogenic carbohydrate moieties of HIV-1 is,
perhaps, one of the current challenges to carbohydrate researchers.
Since the early 1980s when the acquired immunodefiency syndrome
(AIDS) and its etiologic agent, human immunodeficiency virus
(HIV), were first described, the immunological complexity of this
infectious disease has been recognized [55]. For example, discovery
of an oligomannose cluster as the epitope of a broadly HIV-1–
naturalizing antibody, 2G12 [56], has stimulated substantial interest in
such a carbohydrate moiety for the development of HIV-1 vaccines.
However, induction of 2G12-like HIV-1 neutralization antibodies by
active immunizations has been proven difficult [57]. For example, Ni et
al. [58] immunized rabbits using the synthetic oligomannose clusters
that express 2G12 glyco-epitopes and found that this 2G12-positive
antigen elicited only a small fraction of antibodies to the carbohydrate
moieties, with the majority of the IgG-type antibodies being directed to
the linkers in the conjugates. The rabbit anti-sera showed weak cross-
reactivity to HIV-1 gp120.

However, demonstration of the poorly immunogenic 2G12-
oligomannose antigen does not necessarily lead to a conclusion that the
oligomannose antigens are generally non-immunogenic in vivo. This
is because of the fact that the same sugar chain may generate different
glyco-epitopes when the sugar moiety is presented in different cluster
configurations. In essence, the same sugar chains can be assembled
into different antigens; these carbohydrate antigens may interact with
immune systems in different ways. Figure 2A illustrates three examples
of such glyco-epitomics diversity. (Man9)n-KLH (2.) is similar to
(Man9)n-BSA (3.) in the linkage used for coupling oligomannoses
to a protein carrier and in the molar ratio between the Man9 unit
and corresponding carrier. By contrast, [(Man9)4]-KLH (1.) was
constructed by introducing a defined scaffold to display the tetra-valent
oligomannose clusters. Only the latter mimics the high-density Man9-
clusters expressed by the gp120 glycoprotein of HIV-1 [58] and binds
selectively to an HIV-1 neutralization monoclonal antibody (mAb)
2G12 (Figure 2B, blue column). However, a tumor vaccine-elicited
mAb, TM10 [59], is highly reactive with the three Man9 clusters
(Figure 2B, red column). Thus, these glycoconjugates express the TM10
epitope in common but differ in expression of the 2G12 epitope.

Interestingly, the TM10-positive and 2G12-poorly reactive
oligomannose antigens appear to be immunogenic in human and
mice under certain conditions. This is evidenced by the fact that
autoantibodies targeting these oligomannose antigens were found to be
significantly elevated in the blood circulation of men with aggressive
prostate cancers [19,20], in the cerebrospinal fluid of patients with
multiple sclerosis, and in the serum of mice with experimental
autoimmune encephalomyelitis (EAE) [60]. Interestingly, Wang et
al. [60] found that co-immunization of SJL/J mice with a Man9-KLH
conjugate (2.) at the time of EAE induction elicited significant levels
of anti-Man9-cluster autoantibodies (IgG and IgM). Nevertheless, this
anti-glycan autoantibody response was associated with a significantly
reduced clinical severity of EAE. Thus, much remains to be learned
regarding the molecular and cellular mechanisms underlying the

![Figure 1: Schematics of microbial dextran and mammalian glycogen: glycosidic linkages make the difference. The only source of structural diversity in homopolysaccharides is the glycosidic bonds linking the monosaccharides. This figure illustrates two commonly found polysaccharides – one in microbes and another in mammals. The polysaccharide with α(1→4) linkage is dextran, which is found in many bacteria, including Lactobacillaceae. The polysaccharide with the α(1→4) is glycogen and it is found in mammals as one of the biological energy-storage molecules.](image)
differential antibody responses to oligomannose antigens of different cluster configurations.

It is noteworthy that “glyco codes,” the molecular targets of glyco-epitomics study, are not limited to the glyco-epitopes that are defined by anti-glycan antibodies or GBPs. Conceptually, any carbohydrate moiety that plays a role in molecular recognition and bio-communication belongs to this family of bio-communicators. These may include, but are certainly not limited to, the carbohydrates that serve as host receptors of microorganisms [61-64] and those that are specifically recognized by toxins of various origins [65-68]. Glyco-epitope diversity is, therefore, an evolving area of glycomics research and biomarker discovery.

Acknowledgments

I acknowledge Dr. Lai-Xi Wang for reviewing and helpful discussion of this communication. This work is supported in part by NIH grants U01CA128416 and R56AI108388 to DW. The content of this article is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

References

1. Feizi T (2000) Progress in deciphering the information content of the ‘glycome’.-a crescendo in the closing years of the millennium. Glycoconjug J 17: 553-565.
2. Feizi T, Chai W (2004) Oligosaccharide microarrays to decipher the glyco code. Nat Rev Mol Cell Biol 5: 582-586.
3. Taylor ME, Drickamer K (2006) Introduction to Glycobiology. Oxford University Press, New York, USA.
4. Liu Y, Palma AS, Feizi T (2009) Carbohydrate microarrays: key developments in glycobiology. Biol Chem 390: 647-656.
5. Dochez AR, Avery OT (1917) The Elaboration of specific soluble substance by Bacillus anthracis exoporum. J Clin Microbiol 28: 223-231.
6. Wang D, Carroll GT, Turno NJ, Koberstein JT, Kovac P, et al. (2007) Photogenerated glycan arrays identify immunogenic sugar moieties of Bacillus anthracis exoporum. Proteomics 7: 180-184.
7. Schneerson R, Robbins JB, Barrera O, Sutton A, Habib WB, et al. (1980) Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. Prog Clin Biol Res 47: 77-94.
8. Robbins JB, Schneerson R (1990) Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 161: 821-832.
9. Hay A, Rittenhouse-Olson K, Kronenberg M, Apicella MA, Wang D, et al. (2010) Carbohydrate Moieties as Vaccine Candidates: meeting summary. Vaccine 28: 1121-1131.
10. Hakomori S (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405-2414.
11. Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 99: 10231-10233.
12. Wandall HH, Blixt O, Targ MA, Pedersen JW, Bennett EP, et al. (2010) Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 70: 1306-1313.
13. Blixt O, Bueli D, Burford B, Allen D, Julien S, et al. (2011) Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 13: R25.
14. Padier-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, et al. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 71: 3322-3333.
15. Wang D (2012) N-glycan cryptic antigens as active immunological targets in prostate cancer patients. J Proteomics Bioinform 5: 090-095.
16. Wang D, Dafik L, Nolte R, Huang W, Wollinger RD, et al. (2013) Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer. Drug Dev Res 74: 65-80.
17. Behring EA, Kitasato S (1890) The mechanism of immunity in animals to diphtheria and tetanus. Dtsch Med Wochenschr 49: 1113-1114.
18. Wang D, Kabat EA (1998) Antibodies, Specificity. In: Delves PJ, Rolit IM (Eds) Encyclopedia of Immunology, Academic Press London.
19. Drickamer K (1988) Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 263: 9557-9560.
20. Sharon N (2007) Lectins: carbohydrate-specific reagents and biological recognition molecules. J Biol Chem 282: 2753-2764.
21. Blixt O, Kabat EA (1998) Antibodies, Specificity. In: Delves PJ, Rolit IM (Eds) Encyclopedia of Immunology, Academic Press London.
22. Regenmortl MHHV (Ed) Structure of Antigens. CRC Press, Boca Raton. New York, London, Japan.
23. Ezzell JW Jr, Abshire TG, Little SF, Lidgerding BC, Brown C (1990) Identification of Bacillus anthracis by using monoclonal antibody to cell wall galactose-N--acetylgalactosamine polysaccharide. J Clin Microbiol 28: 223-231.
24. Goldberg D, Bern M, North SJ, Haslam SM, Dell A (2009) Glycan family analysis of N-linked and O-linked glycans. Curr Opin Struct Biol 19: 498-506.
25. Goldschmidt B, Hom M, North SJ, Haslam SM, Dell A (2009) Glycan family analysis of N-glycan topology from single MS. Bioinformatics 25: 365-371.
26. Goldberger A, Dharmagoudar R, Czepulkowski B, et al. (2011) Structural characterisation of neoglycans by ultra sensitive mass spectrometric glycans methodology. Glycoconj J 26: 975-986.
27. Petrescu AJ, Butters TD, Reinkensmeier G, Petrescu S, Platt FM, et al. (1997) The solution NMR structure of glucosylated N-glycans involved in the early stages of glycoprotein biosynthesis and folding. EMBO J 16: 4302-4310.
28. Wormald MR, Petrescu AJ, Pao YL, Gilthero A, Elliott T, et al. (2002)
Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev 102: 371-386.

33. Petrescu AJ, Wormald MR, Dwek RA (2006) Structural aspects of glycomes with a focus on N-glycosylation and glycoprotein folding. Curr Opin Struct Biol 16: 600-607.

34. Jo S, Lee HS, Skolnick J, Im W (2013) Restricted N-glycan conformational space in the PDB and its implication in glycan structure modeling. PLoS Comput Biol 9: e1002946.

35. Woods RJ, Tessier MB (2010) Computational glycoscience: characterizing the spatial and temporal properties of glycans and glycan-protein complexes. Curr Opin Struct Biol 20: 579-583.

36. Daubenspeck JM, Zeng H, Chen P, Dong S, Steichen CT, et al. (2004) Novel oligosaccharide side chains of the collagen-like region of BcA, the major glycoprotein of the Bacillus anthracis exosporeum. J Biol Chem 279: 30945-30953.

37. Saksena R, Adamo R, Kováč P (2005) Studies toward a conjugate vaccine for anthrax. Synthesis and characterization of anthrose [4,6-dideoxy-4-(3-hydroxy-3-methylbutanamido)-2-O-methyl-d-glycopyranose] and its methyl glycosides. Carbohydr Res 340: 1591-1600.

38. Saksena R, Adamo R, Kováč P (2007) Immunogens related to the synthetic tetrasaccharide side chain of the Bacillus anthracis exosporeum. Bioorg Med Chem 15: 4283-4310.

39. Borman S (2002) Chemistry Highlights 2002. Carbohydrate Chemistry. Chemical & Engineering News 80: 39-40.

40. Borman S (2012) C&EN Revisits 2002. Carbohydrate Chemistry: Happy Birthday to Microarrays. Chemical & Engineering News 90: 38.

41. Wang D, Collins N (2013) The 10th Anniversary of Carbohydrate Microarrays. J Proteomics Bioinform 7: e24.

42. Kiessling LL, Cairo CW (2002) Hitting the sweet spot. Nat Biotechnol 20: 234-235.

43. Houseman BT, Mrksich M (2002) Carbohydrate arrays for the evaluation of protein binding and enzymatic modification. Chem Biol 9: 443-454.

44. Park S, Shin I (2002) Fabrication of carbohydrate chips for studying protein-carbohydrate interactions. Angew Chem Int Ed Engl 41: 3180-3182.

45. Adams EW, Ratner DM, Bokesch HR, McMahon JB, O’keefe BR, et al. (2004) Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/gp170 interactions. Chem Biol 11: 875-881.

46. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, et al. (2004) Printed carbohydrate microarray. Nat Biotechnol 22: 797-799.

47. Wang D, Liu S, Trummer BJ, Deng C, Wang A (2002) Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat Biotechnol 20: 275-281.

48. Willats WG, Rasmussen SE, Kristensen T, Mikkelsen JD, Knox JP (2002) Sugar-coated microarrays: a novel slide surface for the high-throughput analysis of glycans. Proteomics 2: 1666-1671.

49. Fazio F, Bryan MC, Blixt O, Paulson JC, Wong CH (2002) Synthesis of sugar arrays in microfilter plate. J Am Chem Soc 124: 14397-14402.

50. Fukui S, Feizi T, Galustian C, Lawson AM, Chai W (2002) Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions. Nat Biotechnol 20: 1011-1017.

51. Galanina GE, Mecklenburg M, Nifantiev NE, Pazyagina GV, Bovin NV (2003) GlycoChip: multiarray for the study of carbohydrate-binding proteins. Lab Chip 3: 260-265.

52. Zhou X, Turchi C, Wang D (2009) Carbohydrate cluster microarrays fabricated on three-dimensional dendrimeric platforms for functional glycomics exploration. J Proteome Res 8: 5031-5040.

53. Wang D, Lu J (2004) Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV. Physiol Genomics 18: 245-248.

54. Cisar J, Kabat EA, Domer MM, Liao J (1997) Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. J Exp Med 142: 435-459.

55. Silvestri G (2013) Embracing the complexity of HIV immunology. Immunol Rev 254: 5-9.

56. Calaresa DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.

57. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366.

58. Ni J, Song H, Wang Y, Stamatos NM, Wang LX (2006) Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem 17: 493-500.

59. Newsom-Davis TE, Wang D, Steinman L, Chen PF, Wang LX, et al. (2009) Enhanced immune recognition of cryptic glycan markers in human tumors. Cancer Res 69: 2018-2025.

60. Wang D, Bhat R, Sobel RA, Huang W, Wang LX, et al. (2014) Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Drug Dev Res, (In press).

61. Stevens J, Blixt O, Glaser L, Tauberenberger JK, Palese P, et al. (2006) Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 355: 1143-1155.

62. Chen LM, Blixt O, Stevens J, Lipatov AS, Davis CT, et al. (2012) In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology 422: 105-113.

63. Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS, et al. (2010) Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 84: 12069-12074.

64. Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, et al. (2009) Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol 27: 797-799.

65. Fang Y, Frutos AG, Lahiri J (2002) Membrane protein microarrays. J Am Chem Soc 124: 2394-2395.

66. Huffman DL, Bischof LJ, Griffiths JS, Aroian RV (2004) Pore worms: using Caenorhabditis elegans to study how bacterial toxins interact with their target host. Int J Med Microbiol 293: 599-607.

67. Kim CS, Sao JH, Cha HJ (2012) Functional interaction analysis of GM1-related host. Int J Med Microbiol 293: 599-607.

68. Silvestri G (2013) Embracing the complexity of HIV immunology. Immunol Rev 254: 5-9.